June is Men's Health Month! It's time to focus on the unique health issues men face. K2 Medical Research is dedicated to advancing treatments for conditions like heart disease, prostate cancer, and mental health. Men, take charge of your health today! #MensHealthMonth #K2MedicalResearch
K2 Medical Research’s Post
More Relevant Posts
-
Meet the Team Post - Dr. Craig Curtis, MD, serves as Chief Medical Officer and founder of K2 Medical Research, The Villages and was co-founder of Compass Research, one of the country’s largest and foremost memory loss, Dementia and Alzheimer’s Disease research centers. Dr. Curtis’ research focuses on prevention and treatment of Alzheimer’s Disease and as a collaborator, has been published in leading national and international journals including the New England Journal of Medicine and the Journal of the American Medical Association (JAMA) Neurology. He has been both a local and national lecturer on the topics of Alzheimer’s Disease and clinical research site management. Dr. Curtis began his medical career while proudly serving in the United States Navy. His tour of duty lasted 6 years primarily at the Washington D.C. Naval Yard Medical Clinic, a detachment of Bethesda Naval Hospital. He attended the Univ. of Maryland but obtained his undergraduate degree from Regents College of the State of New York (due to military service) and earned his medical degree from Northeastern Ohio University College of Medicine.
To view or add a comment, sign in
-
-
Happy 4th of July from K2 Medical Research! As we celebrate Independence Day, let's take a moment to appreciate the progress we’ve made in medical research and the future advancements yet to come. Wishing everyone a safe and joyous holiday! #4thOfJuly #IndependenceDay #K2MedicalResearch
To view or add a comment, sign in
-
-
Exciting news! Lilly's #KisunlaTM (donanemab-azbt) has been approved by the #FDA for the treatment of early symptomatic #Alzheimer's disease. In its pivotal Phase 3 study, Kisunla demonstrated significant benefits, including slowing cognitive and functional decline by up to 35% compared to placebo at 18 months. It also reduced the risk of progressing to the next clinical stage of the disease by up to 39%. Kisunla is the first and only amyloid plaque-targeting therapy that offers a limited-duration treatment regimen based on amyloid plaque removal, potentially resulting in lower costs and fewer infusions. This approval brings hope to those affected by Alzheimer's disease and offers the potential to improve their quality of life! #hope #Alzheimersresearch #newtreatment
Breaking News: The FDA approved a new amyloid-targeting therapy to treat adults with early symptomatic #AlzheimersDisease. Learn more: https://e.lilly/4bsaOPk
Latest at Lilly
To view or add a comment, sign in
-
Meet Matt Bubalo, a dedicated leader at K2 Medical Research! With years of experience in clinical research, Matt's commitment to advancing medical science and improving patient outcomes is truly inspiring. Under his guidance, K2 Medical Research, Maitland continues to push the boundaries of innovation and excellence in healthcare. We are proud to have him on our team. #Leadership #HealthcareInnovation #K2MedicalResearch
To view or add a comment, sign in
-
-
Another fun week of supporting the future visionaries of research! 🔬 Our fearless leaders are imparting their extensive research experience on the bright minds of tomorrow. #k2cares #interns #knowledge
To view or add a comment, sign in
-
-
June 20 is The Longest Day, a day dedicated to fighting Alzheimer’s disease. Join K2 Medical Research in supporting those affected by Alzheimer's and their caregivers. Take action today by scheduling a memory screening with K2 Medical Research and participating in an Alzheimer's research study. Your involvement can help advance groundbreaking research, leading to improved treatments and potentially a cure for Alzheimer's. Together, we can make a difference. Go to k2med.com or 321-204-9552 for more information or to schedule your appointment. #TheLongestDay #EndAlzheimers #K2MedicalResearch
To view or add a comment, sign in
-